ArticleMedeniyet medical journal2026
Caspase-8 Polymorphism and Colorectal Cancer Risk: A Meta-Analysis of 35,854 Subjects.
Article in Medeniyet medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Caspase-8 (CASP8) is essential for apoptotic clearance of transformed cells and is encoded by the Methods: Eligible case-control studies published up to January 2025 were systematically retrieved from PubMed, Web of Science, and China National Knowledge Infrastructure. For each study, the association of the CASP8 -652 6N del polymorphism with CRC risk was assessed using odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 22 studies derived from 12 eligible articles involving 15,327 patients with CRC and 20,527 control subjects were enrolled in this meta-analysis. Collectively, the CASP8 -652 6N del variant correlated with reduced CRC risk under the heterozygote genetic model (OR=0.94, 95% CI: 0.89-0.99). When stratifying analyses according to ethnic background, comparable protective associations were detected within Asian populations. By contrast, no statistically meaningful link was identified between this polymorphism and CRC susceptibility among Caucasian individuals. Further stratification based on tumor site revealed no significant correlations for either colon cancer or rectal cancer subgroups. Conclusions: This meta-analysis provides evidence that the CASP8 -652 6N del polymorphism may be linked to a moderately decreased risk of CRC in Asian subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.